citric acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	666	77-92-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: citric acid anhydrous citric acid citric acid monohydrate	A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability. Molecular weight: 192.12 Formula: C6H8O7 CLOGP: -2 LIPINSKI: 0 HAC: 7 HDO: 4 TPSA: 132.13 ALOGS: -0.26 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

citric acid
anhydrous citric acid
citric acid monohydrate

A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.

Molecular weight: 192.12
Formula: C6H8O7
CLOGP: -2
LIPINSKI: 0
HAC: 7
HDO: 4
TPSA: 132.13
ALOGS: -0.26
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
2	g	O

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
June 22, 1982	FDA	BAXTER HLTHCARE

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Toxic epidermal necrolysis	68.43	25.22	30	1878	21616	34933407
Appendicolith	55.61	25.22	20	1888	8581	34946442
Blood phosphorus increased	53.88	25.22	19	1889	7702	34947321
Drug hypersensitivity	48.66	25.22	38	1870	80491	34874532
Appendicitis	45.08	25.22	20	1888	14787	34940236
Myasthenia gravis	40.62	25.22	15	1893	6925	34948098
Dry mouth	36.79	25.22	22	1886	30143	34924880
Ventricular fibrillation	36.75	25.22	20	1888	22934	34932089
Blood uric acid increased	35.86	25.22	15	1893	9609	34945414
Stress	34.09	25.22	21	1887	30326	34924697

Showing 1 to 10 of 13 entries

Previous1 2Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Appendicolith	60.28	18.99	20	3421	8531	79732416
Toxic epidermal necrolysis	54.45	18.99	30	3411	44551	79696396
Blood phosphorus increased	49.03	18.99	18	3423	10329	79730618
Appendicitis	43.03	18.99	20	3421	20774	79720173
Myasthenia gravis	38.12	18.99	15	3426	10384	79730563
Ventricular fibrillation	34.94	18.99	20	3421	31906	79709041
Blood uric acid increased	34.49	18.99	15	3426	13345	79727602
Abdominal distension	33.49	18.99	33	3408	119617	79621330
Drug hypersensitivity	30.85	18.99	50	3391	298866	79442081
Cardiogenic shock	29.92	18.99	20	3421	41894	79699053

Showing 1 to 10 of 19 entries

Previous1 2Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	A09AB04	ALIMENTARY TRACT AND METABOLISM DIGESTIVES, INCL. ENZYMES DIGESTIVES, INCL. ENZYMES Acid preparations
CHEBI has role	CHEBI:33281	antibiotics
CHEBI has role	CHEBI:38161	Chelating agent
CHEBI has role	CHEBI:64049	pH control agents
CHEBI has role	CHEBI:78675	fundamental metabolites
FDA EPC	N0000175835	Calculi Dissolution Agent
FDA EPC	N0000175980	Anti-coagulant
FDA MoA	N0000175089	Calcium Chelating Activity
FDA MoA	N0000175833	Acidifying Activity
FDA PE	N0000008556	Decreased Coagulation Factor Activity

Showing 1 to 10 of 15 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Pain	indication	22253000
Indigestion	indication	162031009
Headache disorder	indication	230461009
Struvite Renal Calculi	indication
Calcium Phosphate Renal Calculi	indication
Renal tubular acidosis	off-label use	1776003	DOID:14219
Cystinuria	off-label use	85020001	DOID:9266
Calcium renal calculus	off-label use	427649000
Calcium Oxalate Renal Calculi	off-label use
Cystine Renal Calculi	off-label use

Showing 1 to 10 of 56 entries

Previous1 2 3 4 5 6Next

🐶 Veterinary Drug Use

Show entries

Search:

Species	Use	Relation
Cattle	Dehydration associated with diarrhea	Indication
Cattle	Early treatment of scouring	Indication
Cattle	Followup treatment following intravenous fluid therapy	Indication

Showing 1 to 3 of 3 entries

Previous1Next

🐶 Veterinary products

Product	Applicant	Ingredients
Re-Sorb, Vytrate	Zoetis Inc.	6

Acid dissociation constants calculated using MoKa v3.0.0

Show entries

Search:

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.49	acidic
pKa2	4.55	acidic
pKa3	5.74	acidic
pKa4	13.14	acidic

Showing 1 to 4 of 4 entries

Previous1Next

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
1%;1.8%;0.4%	PHEXXI	EVOFEM INC	N208352	May 22, 2020	RX	GEL	VAGINAL	10568855	March 15, 2033	PREVENTION OF PREGNANCY
1%;1.8%;0.4%	PHEXXI	EVOFEM INC	N208352	May 22, 2020	RX	GEL	VAGINAL	11337989	March 15, 2033	PREVENTION OF PREGNANCY
12GM/BOT;3.5GM/BOT;10MG/BOT	CLENPIQ	FERRING PHARMS INC	N209589	Nov. 28, 2017	RX	SOLUTION	ORAL	11191753	June 23, 2034	FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY
12GM/BOT;3.5GM/BOT;10MG/BOT	CLENPIQ	FERRING PHARMS INC	N209589	Nov. 28, 2017	RX	SOLUTION	ORAL	9827231	June 26, 2034	FOR CLEANSING THE LARGE INTESTINE AS A PREPARATION FOR COLONOSCOPY

Showing 1 to 4 of 4 entries

Previous1Next

Orange Book exclusivity data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
1%;1.8%;0.4%	PHEXXI	EVOFEM INC	N208352	May 22, 2020	RX	GEL	VAGINAL	May 22, 2023	NEW PRODUCT

Showing 1 to 1 of 1 entries

Previous1Next

Bioactivity Summary:

Show entries

Search:

Target	Class	UniProt	Action	Type	Activity value (-log[M])	Bioact source
3-dehydroquinate dehydratase	Enzyme	AROQ_HELPY		Kd	5.60	CHEMBL
3-dehydroquinate dehydratase	Enzyme	AROQ_STRCO		Kd	5.14	CHEMBL
Transient receptor potential cation channel subfamily V member 4	Ion channel	TRPV4_MOUSE	ACTIVATOR	EC50	5.60	IUPHAR

Showing 1 to 3 of 3 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
CIT	PDB_CHEM_ID
002329	NDDF
002487	NDDF
006406	NDDF
116545009	SNOMEDCT_US
21183	RXNORM
2478	IUPHAR_LIGAND_ID
311	PUBCHEM_CID
4017464	VUID
4017464	VANDF

Showing 1 to 10 of 29 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ACD-A	HUMAN PRESCRIPTION DRUG LABEL	3	0942-0641	SOLUTION	7.30 g	INTRAVENOUS	NDA	2 sections
ACD-A	HUMAN PRESCRIPTION DRUG LABEL	3	0942-0641	SOLUTION	3.65 g	INTRAVENOUS	NDA	2 sections
Alka-Seltzer Extra Strength	HUMAN OTC DRUG LABEL	3	0280-0211	GRANULE, EFFERVESCENT	1000 mg	ORAL	OTC monograph not final	17 sections
Alka-Seltzer Extra Strength	HUMAN OTC DRUG LABEL	3	0280-0211	GRANULE, EFFERVESCENT	1000 mg	ORAL	OTC monograph not final	17 sections
Alka-Seltzer Gold	HUMAN OTC DRUG LABEL	3	0280-4100	TABLET, EFFERVESCENT	1000 mg	ORAL	OTC monograph final	16 sections
Alka-Seltzer Gold	HUMAN OTC DRUG LABEL	3	0280-4100	TABLET, EFFERVESCENT	1000 mg	ORAL	OTC monograph final	16 sections
Alka-Seltzer Heartburn	HUMAN OTC DRUG LABEL	2	0280-0047	TABLET, EFFERVESCENT	1000 mg	ORAL	OTC monograph final	17 sections
Alka-Seltzer Heartburn	HUMAN OTC DRUG LABEL	2	0280-0047	TABLET, EFFERVESCENT	1000 mg	ORAL	OTC monograph final	17 sections
Alka-Seltzer Heartburn Relief Extra Strength	HUMAN OTC DRUG LABEL	2	0280-0079	TABLET, EFFERVESCENT	1000 mg	ORAL	OTC monograph final	16 sections
Alka-Seltzer Heartburn Relief Extra Strength	HUMAN OTC DRUG LABEL	2	0280-0079	TABLET, EFFERVESCENT	1000 mg	ORAL	OTC monograph final	16 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next